基于HPLC-MS和主成分分析的乌梅血清药物化学研究

Serum Pharmacochemistry of Mume Fructus by HPLC-MS and Principal Component Analysis

摘要:

目的: 对比分析乌梅给予大鼠后的入血成分及其代谢产物. 方法: 8只雌性大鼠分为乌梅给药组和空白组,前者灌胃2 mL·kg^-1含0.633 6 g·mL^-1乌梅生药溶液,后者给予同体积纯水.给药4 d后,用固相萃取法提取含药血清及空白血清,用乌梅的乙腈提取液作为乌梅药材对照.色谱采用Angient Zorbax Eclipse Plus C₈色谱柱(3.0 mm×100 mm, 1.8 μm),流动相0.1%甲酸溶液-乙腈梯度洗脱,流速0.5 mL·min^-1;质谱采用ESI源,m/z 50~1 200正离子扫描模式.获得质谱数据用Mzmine 2.9软件进行预处理和主成分分析,利用主成分分析结果和乌梅原型成分数据库对乌梅血中移行成分及代谢物进行鉴定. 结果: 乌梅药材原型入血成分有3种(包括:齐墩果酸或熊果酸以及苜蓿酸),入血后的代谢产物有10种. 结论: 该方法能更客观、全面地分析药材入血成分及其代谢产物,为研究乌梅的药效物质基础提供参考和依据.

Abstract:

Objective: To analyze components and metabolites in serum of rats after given of Mume Fructus by gavage. Method: Eight female rats were divided into Mume Fructus group and blank control group, former group were given Mume Fructus crude solution(0.633 6 g·mL^-1 )2 mL·kg^-1 by gavage, the latter with pure water. Four days later, solid phase extraction method was used to extract the drug-containing serum and blank serum, using Mume Fructus extracted by acetonitrile as medicinal materials control. Chromatography using Angient Zorbax Eclipse Plus C₈(3.0 mm×100 mm, 1.8 μm) for chromatographic column, using 0.1% formic acid solution-acetonitrile gradient elution, flow rate of 0.5 mL·min^-1. Mass spectrometry using ESI source, within the scope of 50-1 200 m/z positive scanning mode. Mass spectrum data were preprocessed and principal component analyzed by Mzmine 2.9 software, using the results of principal component analysis and the database of prototype component to identify blood transitional component and metabolites. Result: In serum there were three components from the Mume Fructus original medicinal herbs(such as ursolic acid or oleanolic acid, medicagenic acid), and there were 10 kinds of the metabolites. Conclusion: This method can be used for analysis of components of medicinal materials into the blood and its metabolites more objective and comprehensive, and it can be used to provide reference and basis for pharmacodynamics research of the Mume Fructus material.